Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Saliva-Based ELISA Tests Measure COVID Neutralizing Antibodies in Multiple Samples at Same Time

By LabMedica International staff writers
Posted on 04 Apr 2022

After any vaccine against the SARS-CoV-2 virus, the body develops neutralizing antibodies which help fight the virus and is thus protective against infections and disease. More...

The degree of protection offered by the vaccine depends on the neutralizing antibodies that are generated by the individual’s immune system. After some time, the neutralizing antibody decreases, and booster doses may be required. Now, two new high-throughput saliva-based ELSIA assays can detect neutralizing activity of samples in response to COVID-19 vaccination.

ReaGene Innovations (Hyderabad, India) has entered into a partnership with Lay Sciences, Inc. (Jupiter, FL, USA) for the development of two patent-pending ELISA and FAST FLOW SPOT diagnostic tests to detect neutralizing activity of samples in response to COVID 19 vaccination. The ELISA diagnostic test can be used in a hospital or pathology lab setting to quantitatively assess multiple samples at the same time. The FAST FLOW SPOT diagnostic test is a single user test that can be used by individuals in a “home” setting. Both diagnostics differ from other tests that measure neutralizing antibodies in blood samples because they only need the individual’s saliva sample. ReaGene will receive royalty payments from Lay Sciences upon the successful launch of the ELISA as well as the FAST FLOW SPOT diagnostic tests.

“Collaboration is important as it requires a concerted team effort to fight and win against a virus like COVID-19 the likes of which we have never seen before. I am also delighted that with the support of Lays Science, we will be able to globally launch these two tests, and which will help us in our fight against COVID-19,” said Dr. Uday Saxena, Scientific Co-Founder of ReaGene Innovations, who led these discoveries.

“These saliva based ELISA and FAST FLOW SPOT diagnostic tests offer yet another line of defense against the onslaught of rapidly evolving SARS-CoV-2 viral variants. These two diagnostic tests are simple and easy-to-use, and this partnership reiterates Lays Sciences’ commitment to fight COVID-19,” added Dr. Satish Chandran, Chief Executive Officer of Lay Science.

Related Links:
ReaGene Innovations
Lay Sciences, Inc. 


Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
HPV Molecular Test
BD Onclarity HPV Assay
New
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.